Constantines Tam News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Constantines Tam. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Constantines Tam Today - Breaking & Trending Today

Broad Superiority of Zanubrutinib Over Bendamustine + Rituximab Across Multiple High-Risk Factors: Biomarker Subgroup Analysis in the Phase 3 SEQUOIA Study in Patients With Treatment-Naive Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Without del(17p)

Published: December 21, 2023

Constantine S. Tam, MD, MBBS, presents the biomarker subgroup analysis from the phase 3 SEQUOIA study investigating zanubrutinib in patients with treatment-naïve chronic lymphocytic leukemia/small lymphocytic lymphoma without del(17p).

Source: onclive.com

Case Study: New Treatment Options for Patients With Chronic Lymphocytic Leukemia

Published: August 2, 2023

With a better understanding of the underlying pathophysiology of chronic lymphocytic leukemia and the introduction of novel targeted agents, such as Bruton kinase Inhibitors, the prognosis of high-risk patients has changed dramatically.

Source: pharmacytimes.com

BeiGene to Demonstrate Strength of Hematology Portfolio and Pipeline at European Hematology Association 2022 Congress

Published: May 12, 2022

Data from four pivotal trials continue to build evidence base for BRUKINSA (zanubrutinib) in B-cell malignancies Pipeline showing promise with early data for BGB-11417, a BCL-2 inhibitor, as monotherapy

Source: finanznachrichten.de

BeiGene to Present Clinical Data from Innovative Oncology Portfolio at 2022 ASCO Annual Meeting

Published: April 27, 2022

Plenary presentation of Phase 3 tislelizumab trial in first-line RM-NPC Primary analysis of zanubrutinib Phase 2 ROSEWOOD trial in follicular lymphoma Long-term data from zanubrutinib Phase 3

Source: finanznachrichten.de